OncoMatch/Clinical Trials/NCT06846346
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma
Is NCT06846346 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ivonescimab and FOLFOX regimen for metastatic esophageal adenocarcinoma.
Treatment: Ivonescimab · FOLFOX regimen · Irinotecan · Paclitaxel — The goal of this clinical trial is to evaluate the addition of ivonescimab to standard chemotherapy in patients with advanced or metastatic gastric and gastroesophageal adenocarcinoma. The main question it aims to answer is : Does the addition of ivonescimab increase the response to treatment ? Participants will visit the clinic every 2 weeks for checkups, treatment administration and tests for collection of adverse events.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) wild-type (HER2-negative)
HER2-negative
Required: CLDN18 wild-type (Claudin 18.2-negative)
Claudin 18.2-negative
Allowed: HER2 (ERBB2) overexpression
HER2-positive
Allowed: CLDN18 overexpression
Claudin 18.2-positive
Allowed: PD-L1 (CD274) overexpression
PD-L1 CPS≥1
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, hemoglobin ≥9 g/dL; no blood transfusion or growth factor therapy within 7 days prior to screening
Kidney function
estimated creatinine clearance ≥50 mL/min or eGFR ≥50 mL/min, urine protein < 2+ or 24-hour urine protein quantification < 1.0 g
Liver function
total bilirubin level ≤1.5 × ULN (≤3 x ULN for patients with liver metastases or confirmed/suspected Gilbert syndrome), AST and ALT ≤2.5 × ULN (≤5 x ULN when documented liver metastasis)
Adequate hematological function: absolute neutrophil count (ANC) ≥1.5 × 10⁹/L, platelet count ≥100 × 10⁹/L, and hemoglobin ≥9 g/dL. Adequate renal function: estimated creatinine clearance ≥50 mL/min... Adequate liver function: total bilirubin level ≤1.5 × ULN (≤3 x ULN for patients with liver metastases or confirmed/suspected Gilbert syndrome), and AST and ALT ≤2.5 × ULN (≤5 x ULN when documented liver metastasis).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify